Published in J Clin Oncol on January 01, 2007
Neoadjuvant hormonal therapy and external-beam radiotherapy versus external-beam irradiation alone for prostate cancer. A quality-of-life analysis. Strahlenther Onkol (2009) 0.78
[Radiotherapy for prostate cancer]. Wien Med Wochenschr (2007) 0.75
Gene expression correlates of clinical prostate cancer behavior. Cancer Cell (2002) 16.27
Comparative effectiveness of minimally invasive vs open radical prostatectomy. JAMA (2009) 7.25
Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol (2007) 6.73
American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin (2010) 6.45
Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst (2007) 5.69
Comorbidity and mortality results from a randomized prostate cancer screening trial. J Clin Oncol (2010) 4.84
Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med (2003) 4.30
Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA (2009) 3.10
Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature. Eur Urol (2013) 2.46
Radical retropubic prostatectomy and robotic-assisted laparoscopic prostatectomy: likelihood of positive surgical margin(s). Urology (2010) 2.31
Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer. BJU Int (2013) 2.18
Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. CA Cancer J Clin (2010) 2.05
Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol (2005) 2.05
Reduced penile size and treatment regret in men with recurrent prostate cancer after surgery, radiotherapy plus androgen deprivation, or radiotherapy alone. Urology (2013) 2.04
Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol (2004) 2.04
Cardiovascular comorbidity and mortality in men with prostate cancer treated with brachytherapy-based radiation with or without hormonal therapy. Int J Radiat Oncol Biol Phys (2013) 2.00
Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J Clin Oncol (2012) 1.86
Which patients with undetectable PSA levels 5 years after radical prostatectomy are still at risk of recurrence?--implications for a risk-adapted follow-up strategy. Urology (2010) 1.83
Predictors of patient preferences and treatment choices for localized prostate cancer. Cancer (2008) 1.66
PSA failure following definitive treatment of prostate cancer having biopsy Gleason score 7 with tertiary grade 5. JAMA (2007) 1.61
Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death. Cancer (2010) 1.59
The likelihood of death from prostate cancer in men with favorable or unfavorable intermediate-risk disease. Cancer (2014) 1.58
Diabetes mellitus, race and the odds of high grade prostate cancer in men treated with radiation therapy. J Urol (2011) 1.58
Predicting the risk of pelvic node involvement among men with prostate cancer in the contemporary era. Int J Radiat Oncol Biol Phys (2009) 1.55
What the U.S. Preventive Services Task Force missed in its prostate cancer screening recommendation. Ann Intern Med (2012) 1.54
Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol (2005) 1.54
Targeting pelvic lymph nodes in men with intermediate- and high-risk prostate cancer despite two negative randomized trials. J Clin Oncol (2008) 1.52
Risk of death from prostate cancer after radical prostatectomy or brachytherapy in men with low or intermediate risk disease. J Urol (2011) 1.52
Time course and predictors of symptoms after primary prostate cancer therapy. J Clin Oncol (2003) 1.51
Impact of race on prostate-specific antigen outcome after radical prostatectomy for clinically localized adenocarcinoma of the prostate. J Clin Oncol (2002) 1.47
Biochemical recurrence after radical prostatectomy for prevalent versus incident cases of prostate cancer : implications for management. Cancer (2008) 1.46
Risk of all-cause and prostate cancer-specific mortality after brachytherapy in men with small prostate size. Int J Radiat Oncol Biol Phys (2010) 1.44
Prostate cancer screening in men 75 years old or older: an assessment of self-reported health status and life expectancy. J Urol (2010) 1.41
Using patient-reported outcomes to assess and improve prostate cancer brachytherapy. BJU Int (2014) 1.39
Impact of national guidelines on brachytherapy monotherapy practice patterns for prostate cancer. Cancer (2013) 1.39
Decision analysis using individual patient preferences to determine optimal treatment for localized prostate cancer. Cancer (2007) 1.37
Recommendations for post-prostatectomy radiation therapy in the United States before and after the presentation of randomized trials. J Urol (2010) 1.29
Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors. Int J Radiat Oncol Biol Phys (2008) 1.27
The impact of a delay in initiating radiation therapy on prostate-specific antigen outcome for patients with clinically localized prostate carcinoma. Cancer (2005) 1.27
Erectile function outcome reporting after clinically localized prostate cancer treatment. J Urol (2007) 1.25
Evidence to support a continued stage migration and decrease in prostate cancer specific mortality. J Urol (2006) 1.19
Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. J Clin Oncol (2012) 1.17
Patient and treatment factors associated with complications after prostate brachytherapy. J Clin Oncol (2006) 1.13
Predictors of mortality after androgen-deprivation therapy in patients with rapidly rising prostate-specific antigen levels after local therapy for prostate cancer. Cancer (2006) 1.04
The 'CaP Calculator': an online decision support tool for clinically localized prostate cancer. BJU Int (2010) 1.04
Salvage radiation in men after prostate-specific antigen failure and the risk of death. Cancer (2011) 1.04
Radiation with or without 6 months of androgen suppression therapy in intermediate- and high-risk clinically localized prostate cancer: a postrandomization analysis by risk group. Int J Radiat Oncol Biol Phys (2009) 1.04
Prostate-specific antigen velocity and survival for patients with hormone-refractory metastatic prostate carcinoma. Cancer (2006) 1.03
Cardiovascular comorbidity and treatment regret in men with recurrent prostate cancer. BJU Int (2011) 1.03
Using the magnitude of PSA bounce after MRI-guided prostate brachytherapy to distinguish recurrence, benign precipitating factors, and idiopathic bounce. Int J Radiat Oncol Biol Phys (2002) 1.02
Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue. Clin Cancer Res (2004) 1.01
Updated results of magnetic resonance imaging guided partial prostate brachytherapy for favorable risk prostate cancer: implications for focal therapy. J Urol (2012) 1.01
Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction. Int J Radiat Oncol Biol Phys (2011) 1.00
PSA velocity is associated with gleason score in radical prostatectomy specimen: marker for prostate cancer aggressiveness. Urology (2008) 0.99
Association of statin and nonsteroidal anti-inflammatory drug use with prostate cancer outcomes: results from CaPSURE. BJU Int (2010) 0.99
Impact of age, benign prostatic hyperplasia, and cancer on prostate-specific antigen level. Cancer (2006) 0.98
Utility of prostate-specific antigen kinetics in addition to clinical factors in the selection of patients for salvage local therapy. J Clin Oncol (2005) 0.98
Late genitourinary and gastrointestinal toxicity after magnetic resonance image-guided prostate brachytherapy with or without neoadjuvant external beam radiation therapy. Cancer (2003) 0.97
Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality. Urology (2006) 0.97
The COMPARE Registry: design and baseline patterns of care for men with biochemical failure after definitive treatment of localized prostate cancer. Urology (2009) 0.97
Gleason Pattern 5 prostate cancer: further stratification of patients with high-risk disease and implications for future randomized trials. Int J Radiat Oncol Biol Phys (2009) 0.97
Models of care and NCCN guideline adherence in very-low-risk prostate cancer. J Natl Compr Canc Netw (2013) 0.95
Mathematical rigor is necessary, but for men with prostate cancer, clinical relevance is the priority. J Clin Oncol (2009) 0.94
Provider case volume and outcomes following prostate brachytherapy. J Urol (2008) 0.94
Influence of year of diagnosis, patient age, and sociodemographic status on recommending adjuvant radiation treatment for stage I testicular seminoma. J Clin Oncol (2008) 0.93
The impact of pathology review on treatment recommendations for patients with adenocarcinoma of the prostate. Urol Oncol (2004) 0.93
Accurate Gleason grading of prostatic adenocarcinoma in prostate needle biopsies by general pathologists. Arch Pathol Lab Med (2003) 0.93
Magnetic resonance spectroscopy-guided transperineal prostate biopsy and brachytherapy for recurrent prostate cancer. Urology (2005) 0.92
Prostate-cancer mortality after PSA screening. N Engl J Med (2012) 0.92
Population-based determinants of radical prostatectomy surgical margin positivity. BJU Int (2010) 0.91
Risk-based management of prostate cancer. N Engl J Med (2011) 0.91
Influence of body mass index on prostate-specific antigen failure after androgen suppression and radiation therapy for localized prostate cancer. Cancer (2007) 0.89
Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer. BJU Int (2012) 0.89
Type of diabetes mellitus and the odds of Gleason score 8 to 10 prostate cancer. Int J Radiat Oncol Biol Phys (2011) 0.89
Evaluating the combined effect of comorbidity and prostate-specific antigen kinetics on the risk of death in men after prostate-specific antigen recurrence. J Clin Oncol (2009) 0.89
PSA outcome following radical prostatectomy for patients with localized prostate cancer stratified by prostatectomy findings and the preoperative PSA level. Urol Oncol (2005) 0.88
Predictors of short postoperative prostate-specific antigen doubling time for patients diagnosed during PSA era. Urology (2005) 0.88
Prediagnostic prostate-specific antigen velocity and probability of detecting high-grade prostate cancer. Urology (2007) 0.87
Perineural invasion associated with increased cancer-specific mortality after external beam radiation therapy for men with low- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys (2006) 0.87
Predicting PSA failure following salvage radiotherapy for a rising PSA post-prostatectomy: from the CaPSURE database. Urol Oncol (2007) 0.87
Determinants of performing radical prostatectomy pelvic lymph node dissection and the number of lymph nodes removed in elderly men. Urology (2010) 0.87
Androgen-suppression therapy for prostate cancer and the risk of death in men with a history of myocardial infarction or stroke. BJU Int (2010) 0.86
Preoperative 3-Tesla multiparametric endorectal magnetic resonance imaging findings and the odds of upgrading and upstaging at radical prostatectomy in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys (2012) 0.86
Prostate-specific antigen doubling time as a surrogate marker for evaluation of oncologic drugs to treat prostate cancer. Clin Cancer Res (2004) 0.86
The effect of minimally invasive and open radical prostatectomy surgeon volume. Urol Oncol (2010) 0.86
Maximal tumor diameter and the risk of PSA failure in men with specimen-confined prostate cancer. Urology (2005) 0.86
Patient-reported quality of life after salvage brachytherapy for radio-recurrent prostate cancer: A prospective Phase II study. Brachytherapy (2009) 0.85
Biological in situ dose painting for image-guided radiation therapy using drug-loaded implantable devices. Int J Radiat Oncol Biol Phys (2009) 0.85
Statin use and the risk of prostate-specific antigen recurrence after radiation therapy with or without hormone therapy for prostate cancer. J Clin Oncol (2010) 0.85
Using PSA, biopsy Gleason score, clinical stage, and the percentage of positive biopsies to identify optimal candidates for prostate-only radiation therapy. Int J Radiat Oncol Biol Phys (2002) 0.85
Quantifying the change in endorectal magnetic resonance imaging-defined tumor volume during neoadjuvant androgen suppression therapy in patients with prostate cancer. Urology (2003) 0.85
Quantifying the impact of seminal vesicle invasion identified using endorectal magnetic resonance imaging on PSA outcome after radiation therapy for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys (2004) 0.85